Comparison of losartan and amlodipine effects on the outcomes of patient with COVID-19 and primary hypertension: A randomised clinical trial.
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
21
10
2020
accepted:
26
02
2021
pubmed:
3
3
2021
medline:
19
5
2021
entrez:
2
3
2021
Statut:
ppublish
Résumé
Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19. In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay. The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241). There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Controversy exists regarding the drug selection in hypertension (HTN) management in patients with COVID-19. This study aimed to compare the effects of losartan and amlodipine in patients with primary HTN and COVID-19.
METHODS
METHODS
In this randomised clinical trial, hospitalised patients with COVID-19 and primary HTN were enrolled in the study. One arm received losartan, 25 mg, twice a day and the other arm received amlodipine, 5 mg per day for 2 weeks. The main outcomes were compare 30-day mortality rate and length of hospital stay.
RESULTS
RESULTS
The mean age of patients treated with losartan (N = 41) and amlodipine (N = 39) was 67.3 ± 14.8 and 60.1 ± 17.3 years, respectively (P value = .068). The length of hospital stay in losartan and amlodipine groups was 4.57 ± 2.59 and 7.30 ± 8.70 days, respectively (P value = .085). Also, the length of ICU admission in losartan and amlodipine group was 7.13 ± 5.99 and 7.15 ± 9.95 days, respectively (P value = .994). The 30-day mortality was two and five patients in losartan and amlodipine groups, respectively (P value = .241).
CONCLUSIONS
CONCLUSIONS
There was no priority in losartan or amlodipine administration in COVID-19 patients with primary HTN in decreasing mortality rate, hospital and ICU length stay. Further studies need to clarify the first-line anti-HTN medications in COVID-19.
Identifiants
pubmed: 33650197
doi: 10.1111/ijcp.14124
pmc: PMC7995089
doi:
Substances chimiques
Antihypertensive Agents
0
Amlodipine
1J444QC288
Losartan
JMS50MPO89
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14124Subventions
Organisme : Tabriz University of Medical Sciences
ID : 65204
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
JAMA. 2019 Dec 17;322(23):2292-2302
pubmed: 31846016
Eur Heart J. 2020 May 14;41(19):1804-1806
pubmed: 32293672
J Am Coll Cardiol. 2000 Nov 1;36(5):1461-6
pubmed: 11079643
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Emerg Microbes Infect. 2020 Dec;9(1):757-760
pubmed: 32228222
Circ Res. 2015 Mar 13;116(6):960-75
pubmed: 25767283
Clin Neurol Neurosurg. 2020 Nov;198:106217
pubmed: 32947193
Adv Pharm Bull. 2020 Sep;10(4):488-489
pubmed: 33062600
Int J Hypertens. 2012;2012:307315
pubmed: 22121476
Am J Hypertens. 2020 Dec 31;33(12):1102-1111
pubmed: 32920644
JAMA. 2020 May 12;323(18):1769-1770
pubmed: 32208485
Lancet Respir Med. 2020 Apr;8(4):e21
pubmed: 32171062
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Int J Mol Med. 2012 Feb;29(2):269-76
pubmed: 22020765
Hypertens Res. 2020 Nov;43(11):1257-1266
pubmed: 32820236
J Am Soc Nephrol. 2007 Apr;18(4):1093-102
pubmed: 17329576
Cureus. 2020 May 12;12(5):e8069
pubmed: 32411566
Int J Chron Obstruct Pulmon Dis. 2018 Mar 08;13:867-874
pubmed: 29563786
Proc (Bayl Univ Med Cent). 2018 Oct 26;31(4):419-423
pubmed: 30948970
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Int J Clin Pract. 2021 Jun;75(6):e14124
pubmed: 33650197
J Med Virol. 2020 Oct;92(10):1731-1732
pubmed: 32239515
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
Hypertens Res. 2008 Mar;31(3):553-9
pubmed: 18497476
Infect Control Hosp Epidemiol. 2020 Jun;41(6):752-753
pubmed: 32248854
Trends Cardiovasc Med. 2020 Apr;30(3):160-164
pubmed: 31521481
Arch Biochem Biophys. 2009 Jan 1;481(1):131-6
pubmed: 18940180
Biochem J. 2004 Oct 1;383(Pt 1):45-51
pubmed: 15283675
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Nature. 2020 Sep;585(7823):16-17
pubmed: 32860026
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Curr Hypertens Rep. 2020 Jun 13;22(6):43
pubmed: 32535705
J Am Heart Assoc. 2015 Dec 07;4(12):
pubmed: 26643500
Am J Physiol Regul Integr Comp Physiol. 2009 Feb;296(2):R208-16
pubmed: 19073907